Receptor-based QSAR studies of non-peptide human oxytocin receptor antagonists

Journal of Molecular Graphics and Modelling

Volumn 25, Issue 5, 2007, Pages 711-720

  Jójárt, Balázs ^a   Márki, Árpád ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Benzoxazinone antagonists; CoMFA with q2 GRS; Human oxytocin receptor; Receptor based QSAR; Scoring function

Indexed keywords

AMINO ACIDS; BIOSYNTHESIS; MATHEMATICAL MODELS; MOLECULAR STRUCTURE;

BENZOXAZINONE ANTAGONISTS; HUMAN OXYTOCIN RECEPTORS; RECEPTOR-BASED QSAR; SCORING FUNCTIONS;

PROTEINS;

BENZOXAZINONE DERIVATIVE; HORMONE RECEPTOR BLOCKING AGENT; OXYTOCIN RECEPTOR;

ARTICLE; CALCULATION; DATA ANALYSIS; DRUG ACTIVITY; DRUG STRUCTURE; HORMONE RECEPTOR INTERACTION; HUMAN; LIGAND BINDING; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SCORING SYSTEM; VALIDATION STUDY;

BENZOXAZINES; COMPUTER SIMULATION; ELECTROSTATICS; HUMANS; HYDROGEN-ION CONCENTRATION; MODELS, MOLECULAR; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, OXYTOCIN; SOFTWARE; THERMODYNAMICS;

EID: 33846693375     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2006.05.010     Document Type: Article

References (37)

1. Cramer III R.D., Patterson D.E., and Jeffrey D.B. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110 (1998) 5959-5967
2. Kubinyi H., Folkers G., and Martin Y.C. 3D QSAR in Drug Design-Recent Advances vol. 3 (1998), Kluwer Escom, London pp. 317-338
3. Goodford P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28 (1985) 849-857
4. Kubinyi H., Folkers G., and Martin Y.C. 3D QSAR in Drug Design-Recent Advances vol. 3 (1998), Kluwer Escom, London pp. 199-214
5. Datar P., Desai P., Coutinho E., and Iyer K. CoMFA and CoMSIA studies of angiotensin (AT1) receptor antagonists. J. Mol. Model. 8 (2002) 290-301
6. Gether U. Uncovering molecular mechanisms involved in activation of g protein-coupled receptors. Endocr. Rev. 21 (2000) 90-113
7. Fredriksson R., Lagerström M.C., Lundin L.-G., and Schiöth H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63 (2003) 1256-1272
8. Ji T.H., Grossmann M., and Ji H. G protein-coupled receptors. I. Diversity of receptor-ligand interactions. J. Biol. Chem. 273 (1998) 17299-17302
9. Ashton M., Charlton M.H., Schwarz M.K., Thomas R.J., and Whittaker M. The selection and design of GPCR ligands: from concept to the clinic. Comb. Chem. HTS 7 (2004) 441-452
10. Evers A., Hessler G., Matter H., and Klabunde T. Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. J. Med. Chem. 48 (2005) 5448-5465
11. Evers A., and Klabunde T. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J. Med. Chem. 48 (2005) 1088-1097
12. Bock J.R., and Gough D.A. Virtual screen for ligands of orphan G protein-coupled receptors. J. Chem. Inf. Model. 45 (2005) 1402-1414
13. Kruse J. Oxytocin: pharmacology and clinical application. J. Family Pract. 23 (1986) 473-479
14. Schwarz M.K., and Page P. Preterm labour: an overview of current and emerging therapeutics. Curr. Med. Chem. 10 (2003) 1441-1468
15. 2 vasopressin receptor. J. Biol. Chem. 271 (1996) 31593-31601
16. Hawtin S.R., Howard H.C., and Whetaley M. Identification of an extracellular segment of the oxytocin receptor providing agonist-specific binding epitopes. Biochem. J. 354 (2001) 465-472
17. Jójárt B., Martinek T.A., and Márki A. The 3D structure of the binding pocket of the human oxytocin receptor for benzoxazine antagonists, determined by molecular docking, scoring functions and 3D-QSAR methods. J. Comput.-Aided Mol. Des. 19 (2005) 341-356
18. Giełdoñ A., Kaźmierkiewicz R., Ślusarz R., and Ciarkowski J. Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors. J. Comput.-Aided. Mol. Des. 15 (2002) 1085-1104
19. Pogozheva I.D., Lomize A.L., and Mosberg H.I. Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. Biophys. J. 75 (1998) 612-634
20. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Le Trong I., Teller D.C., Okada T., Stenkamp R.E., Yamamoto M., and Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 (2000) 739-745
21. Jójárt B., and Márki A. Possible dynamic anchor points in a benzoxazinone derivative-human oxytocin receptor system-a molecular docking and dynamics calculation, and the possible electrostatic and hydrophobic anchor points were determined by means of structural and energetical filters of the dynamic complex. J. Mol. Model. 13 (2007) 1-10
22. Wyatt P.G., Allen M.J., Chilcott J., Foster A., Livermore D.G., Mordaunt J.E., Scicinski J., and Woollard P. Identification of potent and selective oxytocin antagonists. Part 1. Indole and benzofuran derivatives. Bioorg. Med. Chem. Lett. 12 (2002) 1399-1404
23. Wyatt P.G., Allen M.J., Chilcott J., Gardner C.J., Livermore D.G., Mordaunt J.E., Nerozzi F., Patel M., Perren M.J., Weingarten G.G., Shabbir S., Wollard P.M., and Zhou P. Identification of potent and selective oxytocin antagonists. Part 2. Further investigation of benzofuran derivatives. Bioorg. Med. Chem. Lett. 12 (2002) 1405-1411
24. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19 (1998) 1639-1662
25. Mehler E.L., and Solmajer T. Electrostatic effects in proteins: comparison of dielectric and charge models. Protein Eng. 4 (1991) 903-910
26. Molecular Operating Environment, Version 2005.06 (2005), CCG Inc., Montreal, Quebec, Canada
27. Halgren T.A. Merck molecular force field. I. Basis, form, scope, parametrization, and performance of MMFF94. J. Comput. Chem. 17 (1996) 490-519
28. Halgren T.A. Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. J. Comput. Chem. 17 (1996) 520-552
29. Halgren T.A. Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94. J. Comput. Chem. 17 (1996) 553-586
30. Halgren T.A. Merck molecular force field. IV. Conformational energies and geometries for MMFF94. J. Comput. Chem. 17 (1996) 587-615
31. Halgren T.A. Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data, and empirical rules. J. Comput. Chem. 17 (1996) 616-641
32. Mackerrel Jr. A.D. Empirical force fields for biological macromolecules: overview and issues. J. Comput. Chem. 25 (2004) 1584-1604
33. Wang R., Lai L., and Wang S. Further development and validation of empirical scoring functions for structure-based binding affinity prediction. J. Comput.-Aided Mol. Des. 16 (2002) 11-26
34. Cho S.J., and Tropsha A. Cross-validated R2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results. J. Med. Chem. 38 (1995) 1060-1066
35. Sybyl Molecular Modeling System, Version 7.1, Tripos Associates, St. Louis, MO, 2005
36. Novellino E., Fattorusso C., and Greco G. Use of comparative molecular field analysis and cluster analysis in series design. Pharm. Acta Helv. 70 (1995) 149-154
37. Kubinyi H., Hamprecht F.A., and Mietzner T. Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices. J. Med. Chem. 41 (1998) 2553-2564